News Article | April 17, 2017
Boston, MA - South Carolina saw a 22 percent reduction in post-surgical deaths in hospitals that completed a voluntary, statewide program to implement the World Health Organization Surgical Safety Checklist. The findings of the five-year project between the South Carolina Hospital Association, Ariadne Labs, and Harvard T.H. Chan School of Public Health will appear in the August 2017 print issue of the Annals of Surgery and is published online. The study is the first to demonstrate large-scale population-wide impact of the checklist. "That is a major reduction in post-surgical mortality and it demonstrates that when done right, the Surgical Safety Checklist can significantly improve patient safety at large scale," said lead author Dr. Alex B. Haynes, associate director of the Ariadne Labs Safe Surgery Program and a surgeon at Massachusetts General Hospital. Adoption of a safe surgery checklist has been demonstrated to reduce deaths in controlled research studies since 2009. But the ability to produce improved outcomes at large scale has remained questioned. In the Safe Surgery South Carolina program, all hospitals in the state were invited to participate in a voluntary, statewide effort to complete a twelve-step implementation program with Ariadne Labs that included customizing the checklist for the local setting, doing small scale testing, and observing and coaching on checklist performance. Fourteen hospitals, representing nearly 40 percent of the inpatient surgery volume in the state, completed the program. Researchers compared the 30-day post-surgery mortality outcomes between these hospitals with the mortality outcomes of the rest of the hospitals in the state. Surgical procedures in the analysis represent a wide range of specialties, from neurological, thoracic and cardiac, to soft tissue and orthopedic. The study found that the post-surgery death rate in the 14 hospitals that completed the program was 3.38 percent in 2010 (prior to implementation) and fell to 2.84 percent in 2013 after implementation. In the other 44 hospitals in the state, mortality was 3.5 percent in 2010 and 3.71 percent in 2013. This corresponded to a 22 percent difference in mortality between the groups. With these results, South Carolina offers a national model of best practices in implementing a team-based, communication checklist to drive quality improvement in the operating room. "We are honored to be a learning lab for the rest of the country," said Thornton Kirby, President and CEO of the South Carolina Hospital Association. "The study validates what we hoped and believed from the outset -- if you change the operating room culture of how you communicate and coordinate your efforts, you can produce better outcomes." Ariadne Labs' Executive Director Dr. Atul Gawande led the development of the WHO Surgical Safety Checklist in 2008 with a team of international experts. The 19-item checklist prompts surgical team discussion of the surgical plan, risks, and concerns. Following surgery, patients are at risk of complications and death from a variety of causes such as infection, hemorrhage, and organ failure. Collectively, the checklist items create a culture of operating room communication that improves overall surgical care and safety. Evidence from a 2009 pilot study with selected operating teams in eight countries around the world demonstrated a 47 percent decrease in post-surgical mortality. Further studies went on to confirm the powerful effect. But translating the checklist into population-wide mortality reduction has not been proven until now. "Safety checklists can significantly reduce death in surgery. But they won't if surgical teams treat them as just ticking a box," said Gawande. "With this work, South Carolina has demonstrated that surgery checklists can save lives at large scale -- and how hospitals can support their teams to do it." Visit the Harvard Chan School website for the latest news, press releases, and multimedia offerings. Ariadne Labs is a global leader in health systems innovation, fostering a new discipline of research and discovery for better patient care from birth to surgery to the end of life. A joint center of Brigham & Women's Hospital and the Harvard T.H. Chan School of Public Health, Ariadne Labs was founded by public health researcher and surgeon Dr. Atul Gawande. The mission is to develop simple, high-impact and scalable solutions that reduce suffering and save lives at the most critical moments in people's lives everywhere. The South Carolina Hospital Association (SCHA) is a private, not-for-profit organization made up of some 100 member hospitals and health systems. Established in 1921 to serve as the collective voice of the state's hospital community, SCHA is proud to be a part of the state's hospital industry, adding value to hospitals' efforts to care for the people of South Carolina. By helping to keep South Carolina's hospitals healthy, we are helping to keep our state healthy. Harvard T.H. Chan School of Public Health brings together dedicated experts from many disciplines to educate new generations of global health leaders and produce powerful ideas that improve the lives and health of people everywhere. As a community of leading scientists, educators, and students, we work together to take innovative ideas from the laboratory to people's lives--not only making scientific breakthroughs, but also working to change individual behaviors, public policies, and health care practices. Each year, more than 400 faculty members at Harvard Chan School teach 1,000-plus full-time students from around the world and train thousands more through online and executive education courses. Founded in 1913 as the Harvard-MIT School of Health Officers, the School is recognized as America's oldest professional training program in public health.
News Article | May 5, 2017
WASHINGTON, DC--(Marketwired - May 5, 2017) - Snipp Interactive Inc. ("Snipp" or the "Company") (TSX VENTURE:SPN)(OTCQX:SNIPF), an international provider of marketing promotions, rebates and loyalty solutions listed on the OTCQX and the TSX Venture Exchange ("TSX-V"), is pleased to announce a non-brokered private placement for gross proceeds of up to CAD $4.5 million (the "Financing"). The Financing will be comprised of up to 45,000,000 common shares ("Shares") at a market price of CAD $0.10 per Share. Closing of the Financing will close in tranches. It is expected that the first tranche of the Financing will close promptly after the TSX-V has approved of the Financing. As Snipp has received indications of interest from certain of its insiders, it is expected that the second tranche of the Financing will close upon Snipp obtaining any required shareholder approvals at its upcoming annual general and special meeting in the event any such insider becomes a "Control Person", as required by the policies of the TSX-V. All Shares issued pursuant to the Financing will be subject to a four-month hold period under applicable securities laws in Canada, as well as the policies of the TSX-V, where applicable. Finder's fees may be payable to certain finders in connection with the Financing, subject to the approval of the TSX-V. Existing shareholders are welcome to call or email the Company if they are interested in subscribing in the Financing. The Company is making this offer available in good faith to existing shareholders who would like to participate in the Financing. Any shareholder wishing to participate in the Financing must qualify for an exemption from the prospectus requirements pursuant to National Instrument 45-106. The net proceeds raised through the Financing will be used for sales & marketing and general working capital purposes. "As noted in our news release of May 2, 2017, Snipp has completed a major phase of investment in engineering and product development, and we are now turning our attention to focus on our sales and marketing efforts" said Atul Sabharwal, CEO of Snipp. "With this round of funding, we will be in a very strong position to devote significant resources to these efforts and work towards our goal of rapidly reaching cash flow breakeven and profitability." Snipp is a global loyalty and promotions company with a singular focus: to develop disruptive engagement platforms that generate insights and drive sales. Our solutions include shopper marketing promotions, loyalty, rewards, rebates and data analytics, all of which are seamlessly integrated to provide a one-stop marketing technology platform. We also provide the services and expertise to design, execute and promote client programs. SnippCheck, our receipt processing engine, is the market leader for receipt-based purchase validation; SnippLoyalty is the only unified loyalty solution in the market for CPG brands. Snipp has powered hundreds of programs for Fortune 1000 brands and world-class agencies and partners. Snipp is headquartered in Washington, DC with offices across the United States, Canada, UK, Ireland, Europe and India. The company is publicly listed on the OTCQX, the highest tier of the OTC market in the United States of America, and on the Toronto Stock Venture Exchange (TSX) in Canada. Snipp was selected to the TSX Venture 50®, an annual ranking of the strongest performing companies on the TSX Venture Exchange, in 2015 and 2016. SNIPP IS RANKED #49 AMONGST THE FASTEST GROWING COMPANIES IN NORTH AMERICA ON DELOITTE'S 2016 TECHNOLOGY FAST 500™ LIST. EXISTING SHAREHOLDERS WISHING TO PARTICIPATE IN THE FINANCING, PLEASE CONTACT: This press release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause our actual results to differ materially from the statements made, including: (a) those factors discussed in filings made by us with the Canadian securities regulatory authorities; (b) the risk that the Financing may not be completed on the terms contemplated above; (c) the economic circumstance of Snipp may change and result in the proceeds of the Financing being used other than in the manner described above; or (d) reaching cash flow breakeven or profitability. Should one or more of these risks and uncertainties, such as changes in demand for and prices for the products of the Company or the materials required to produce those products, labour relations problems, currency and interest rate fluctuations, increased competition and general economic and market factors, occur or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward-looking statements, except as required by law. The reader is cautioned not to put undue reliance on such forward-looking statements. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer for sale in the United States. The securities being offered have not been, nor will be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements. Copyright Snipp Interactive Inc. All rights reserved. All other trademarks and trade names are the property of their respective owners.
News Article | May 6, 2017
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NantHealth, Inc. (“NantHealth” or the “Company”) (NASDAQ:NH) of the May 8, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased NantHealth securities in connection with the Company’s initial public offering on or about June 1, 2016 (the “IPO”), and/or between June 1, 2016 and March 6, 2017 (the “Class Period”). The case, Atul Singh Deora v. NantHealth, Inc. et al, No. 2:17-cv-01825 was filed on March 7, 2017, and has been assigned to Judge Beverly Reid O'Connell. The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) NantHealth founder, Patrick Soon-Shiong (“Soon-Shiong”), had donated funds through nonprofit organizations to the University of Utah for the purpose of funneling those funds back into NantHealth; (2) as such, the Company and Soon-Shiong participated in the violation of federal tax laws which exposes the Company to possible civil and criminal liability; (3) NantHealth improperly recorded orders received from the University of Utah as GPS Cancer test orders; (4) consequently, the Company reported false GPS Cancer order figures for the third quarter of 2016; and (5) as a result, the Company’s financial statements and statements about its business, operations, and prospects were materially false and/or misleading. Specifically, on March 6, 2017, STAT, a news organization focused on medical industry reporting, published an article alleging that Soon-Shiong had donated $12 million to the University of Utah from three different tax-exempt entities controlled by him under a contract that required the University to funnel much of that money into NantHealth. Additionally, STAT alleged that NantHealth misled investors in reporting its third-quarter earnings in November 2016. The Company claimed that it had received 524 orders for the GPS Cancer test, and that one-third of those orders came from the University of Utah deal, but that the geneticist leading the research told STAT that the work they ordered from NantHealth had nothing to do with GPS Cancer. On this news, NantHealth’s share price fell from $7.17 per share on March 3, 2017 to a closing price of $5.50 on March 6, 2017 —a $1.67 or a 23.29% drop. Request more information now by clicking here: www.faruqilaw.com/NH. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding NantHealth’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
News Article | April 30, 2017
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NantHealth, Inc. (“NantHealth” or the “Company”) (NASDAQ:NH) of the May 8, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased NantHealth securities in connection with the Company’s initial public offering on or about June 1, 2016 (the “IPO”), and/or between June 1, 2016 and March 6, 2017 (the “Class Period”). The case, Atul Singh Deora v. NantHealth, Inc. et al, No. 2:17-cv-01825 was filed on March 7, 2017, and has been assigned to Judge Beverly Reid O'Connell. The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) NantHealth founder, Patrick Soon-Shiong (“Soon-Shiong”), had donated funds through nonprofit organizations to the University of Utah for the purpose of funneling those funds back into NantHealth; (2) as such, the Company and Soon-Shiong participated in the violation of federal tax laws which exposes the Company to possible civil and criminal liability; (3) NantHealth improperly recorded orders received from the University of Utah as GPS Cancer test orders; (4) consequently, the Company reported false GPS Cancer order figures for the third quarter of 2016; and (5) as a result, the Company’s financial statements and statements about its business, operations, and prospects were materially false and/or misleading. Specifically, on March 6, 2017, STAT, a news organization focused on medical industry reporting, published an article alleging that Soon-Shiong had donated $12 million to the University of Utah from three different tax-exempt entities controlled by him under a contract that required the University to funnel much of that money into NantHealth. Additionally, STAT alleged that NantHealth misled investors in reporting its third-quarter earnings in November 2016. The Company claimed that it had received 524 orders for the GPS Cancer test, and that one-third of those orders came from the University of Utah deal, but that the geneticist leading the research told STAT that the work they ordered from NantHealth had nothing to do with GPS Cancer. On this news, NantHealth’s share price fell from $7.17 per share on March 3, 2017 to a closing price of $5.50 on March 6, 2017 — a $1.67 or a 23.29% drop. Request more information now by clicking here: www.faruqilaw.com/NH. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding NantHealth’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
News Article | April 29, 2017
— The global Dyes market is valued at 8149.95 million USD in 2016 and is expected to reach 11024.85 million USD by the end of 2022, growing at a CAGR of 5.16% between 2016 and 2022. Companies profiled in this report are Archroma, Huntsman, Kiri Industries, Nippon Kayaku, Kyung-In, Colourtex, Jay Chemicals, Everlight Chemical, BEZEMA, Bodal Chemical, Sumitomo, Eksoy, Aarti Industries Ltd, Osaka Godo, Setas, Atul, Anand International, LonSen, Runtu, Jihua Group, Transfar, Hubei Chuyuan, Tianjin Hongfa, YaBuLai Dyestuff, Yabang, Linfen Dyeing, Dalian Dyestuffs, Zhongdan, ANOKY, Tianjin Dek Chemical, Zhejiang Jinguang Industrial, Matex Chemicals and more. Analysis by Product Types, with production, revenue, price, market share and growth rate of each type, can be divided into • Disperse Dyes • Reactive Dyes • Sulfur Dyes • Vat Dyes • Acid Dyes • Other Analysis by Applications, this report focuses on consumption, market share and growth rate of Dyes in each application, can be divided into • Textile • Leather • Paper • Other Table of Contents: 1 Dyes Market Overview 2 Global Dyes Competition by Players, Type and Application 3 USA Dyes (Sales, Revenue and Price) 4 China Dyes (Sales, Revenue and Price) 5 Europe Dyes (Sales, Revenue and Price) 6 Northeast Asia Dyes (Sales, Revenue and Price) 7 India Dyes (Sales, Revenue and Price) 8 Southeast Asia Dyes (Sales, Revenue and Price) 9 Global Dyes Players Profiles and Sales Data 10 Dyes Manufacturing Cost Analysis 11 Industrial Chain, Sourcing Strategy and Downstream Buyers 12 Marketing Strategy Analysis, Distributors/Traders 13 Market Effect Factors Analysis 14 Global Dyes Market Forecast (2017-2023) 15 Research Findings and Conclusion 16 Methodology and Data Source Inquire more about this report at: https://www.themarketreports.com/report/ask-your-query/482910 For more information, please visit https://www.themarketreports.com/report/global-dyes-sales-market-report-2017
News Article | April 17, 2017
The PBS Frontline documentary “Being Mortal” delves into the hopes of patients and families facing terminal illness. The film investigates the practice of caring for the dying and explores the relationships between patients and their doctors. It follows a surgeon, Dr. Atul Gawande, as he shares stories from the people and families he encounters. When Dr. Gawande’s own father gets cancer, his search for answers about how best to care for the dying becomes a personal quest. The film sheds light on how a medical system focused on a cure often leaves out the sensitive conversations that need to happen so a patient’s true wishes can be known and honored at the end. Center for Hospice Care and its supporting foundation, Hospice Foundation, are hosting a free dinner and learn screening of the documentary as a way to help initiate the tough, but necessary, conversations about end-of-life decisions. Mike Wargo, Hospice Foundation Vice President and COO said, "We chose 'Being Mortal' because it underscores the importance of planning ahead and talking with family members about these important decisions." Following the screening of the documentary a guided discussion of the film will be led by a panel of end-of-life experts including Mark Sandock, MD, a local physician consultant; Mark Murray, President and CEO of Center for Hospice Care; and Dominic Vachon, Director of the Ruth M. Hillebrand Center for Compassionate Care in Medicine at the University of Notre Dame. According to recent studies, 70 percent of Americans say they would prefer to die at home, but nearly 70 percent die in hospitals and institutions. Ninety percent of Americans know they should have conversations about end-of-life care, yet only 30 percent have done so. In February 2015, “Being Mortal” aired nationally on the PBS program “Frontline.” For more information about the film, visit http://www.pbs.org/wgbh/pages/frontline/being-mortal/. The film is adapted from Dr. Gawande’s 2014 nationally best selling book of the same name. More information about the book is at http://atulgawande.com/book/being-mortal/. The free screening is made possible by a grant from The John and Wauna Harman Foundation in partnership with the Hospice Foundation of America. A complimentary sandwich/soup/salad buffet will be available for those who reserve a seat in advance. Seating is limited. The event will begin at 5:30 pm at Center for Hospice Care, 501 Comfort Pl, Mishawaka, IN. To RSVP, contact Cyndy Searfoss at 574.277.4203 or at searfossc(at)cfhcare(dot)org.
News Article | April 26, 2017
Thousands of researchers will gather in San Francisco May 6-9 to share latest findings in a wide range of fields that will help define health care for a new generation. SAN FRANCISCO - Leading experts will present thousands of original research abstracts in children's health at the 2017 Pediatric Academic Societies Meeting, the largest international meeting focused on research in child health. Among the research to be presented at PAS are abstracts that will highlight new findings in treating newborns who have been exposed to opioids, the impact of marijuana legalization on teens, the impact of digital media use on children's literacy, concussions in young athletes, lead exposure among children in poverty, the Zika virus, autism, adolescent depression, diet-related cardiovascular changes in children and the effects of losing health insurance on children's health. The conference takes place May 6-9 at the Moscone West Convention Center in San Francisco. Thousands of research scientists, health care providers and policy makers from around the world are expected to attend the meeting. Journalists will have access to scientists sharing original pediatric research, and thousands of scientific papers will be presented before they appear in medical journals. "The opportunity to share original research as it unfolds remains at the heart of the Pediatric Academic Societies meeting," said Clifford W. Bogue, MD, FAAP, PAS program committee chair and a professor of pediatrics at Yale School of Medicine. "But what's equally critical to keep pace with rapidly evolving child health issues is the chance to discuss with colleagues from around the globe how this research can be applied to actual clinical practice in pediatrics, as well as public policy and advocacy," he said. The 2017 meeting will include hundreds of research abstracts that will be presented in platform and poster sessions. Information sessions, workshops and plenary talks throughout the four-day meeting will explore a comprehensive array of issues affecting current and future approaches to pediatric health care. Atul Butte, MD, PhD, a pediatrician, computer scientist and biomedical infomatics pioneer will deliver the keynote address, exploring looking to "big data" for new, more targeted and effective cures for children. In his talk, "Translating Ten Trillion Points of Data into Therapies, Diagnostics, and New Insights into Disease," he will describe the emerging field of "precision medicine," which incorporates vast new knowledge of human genetics and other publicly available molecular data, along with its myriad social complexities. Dr. Butte is inaugural Director of the Institute for Computational Health Sciences, Professor of Pediatrics at UCSF, and Executive Director for Clinical Informatics, University of California Health Sciences and Services. Journalists should register in advance. Individuals who do not meet the criteria for media credentials will not be awarded a press badge on-site. To apply for media credentials, email Susan Martin (email@example.com) and Emily James (firstname.lastname@example.org) with the following information: For more information about the 2017 PAS Meeting, visit http://www. . The Pediatric Academic Societies (PAS) Meeting brings together thousands of individuals united by a common mission: to improve child health and wellbeing worldwide. This international gathering includes pediatric researchers, leaders in academic pediatrics, experts in child health, and practitioners. The PAS Meeting is produced through a partnership of four organizations leading the advancement of pediatric research and child advocacy: the Academic Pediatric Association, American Academy of Pediatrics, American Pediatric Society, and Society for Pediatric Research. For more information, visit the PAS Meeting online at http://www. , follow us on Twitter @PASMeeting and #pasm17, or like us on Facebook.
News Article | April 24, 2017
Global Epoxy Active Diluent Industry Report covering market by types, Regions, Application, and leading vendor’s profile based on sales, price, sales regions, products, profile etc.Pune, India - April 24, 2017 /MarketersMedia/ — Global Epoxy Active Diluent Market 2012- 2022 Report provides detailed analysis of market in 9 chapters with required tables and figures. Access this report at https://www.themarketreports.com/report/global-epoxy-active-diluent-market-research-2011-2022 Global Epoxy Active Diluent Market report classifies Epoxy Active Diluent types as Monofunctional, Bifunctional and Trifunctional. Applications covered in this report are Coating, Adhesive, Electrical and Electronic Materials and Engineering Plastic. This report also provides key analysis for the geographical regions like Europe, North America, China, Japan & Korea. Companies like Dow Chemical, Huntsman, Hexion, BASF, Aditya Birla Chemicals, SACHEM, EMS-GRILTECH, Atul, Air Products, Kukdo, LEUNA-Harze, Adeka, Arkema, King Industries, Sakamoto Yakuhin Kogyo, Arnette Polymers, Yuvraj Chemicals, Cardolite, Royce and more are profiled in this report providing information on sale, price, sales regions, products and overview. Purchase a copy of this report at: https://www.themarketreports.com/report/buy-now/483936 Table of Contents: 1 Market Overview 1.1 Objectives of Research 1.2 Market Segment 2 Industry Chain 2.1 Industry Chain Structure 2.2 Upstream 2.3 Market 3 Environmental Analysis 3.1 Policy 3.2 Economic 3.3 Technology 3.4 Market Entry 4 Major Vendors 5 Market/Vendors Distribution 5.1 Regional Distribution 5.2 Product and Application 6 Regions Market 6.1 Global 6.2 Europe 6.3 North America 6.4 China 6.5 Japan & Korea 6.6 Trade 7 Forecast 7.1 Market Trends 7.2 Segment Forecast 8 Marketing Overview 8.1 Ex-factory Price 8.2 Buyer Price 8.3 Price Factors 8.4 Marketing Channel 9 Conclusion Inquire more about this report at: https://www.themarketreports.com/report/ask-your-query/483936 Contact Info:Name: Shirish GuptaEmail: email@example.comOrganization: The Market ReportsAddress: SF-29, Sacred World, Wanawadi, PunePhone: 6314071315Source URL: http://marketersmedia.com/global-epoxy-active-diluent-market-is-estimated-to-reach-1-4-billion-usd-in-2017/189609For more information, please visit https://www.themarketreports.com/report/global-epoxy-active-diluent-market-research-2011-2022Source: MarketersMediaRelease ID: 189609
News Article | February 23, 2017
Research and Markets has announced the addition of the "Global Cresol Market Analysis & Trends - Industry Forecast to 2025" report to their offering. The Global Cresol Market is poised to grow at a CAGR of around 4.3% over the next decade to reach approximately $880.5 million by 2025. This industry report analyzes the market estimates and forecasts for all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors. Some of the prominent trends that the market is witnessing include rising consumer demand for vitamin E, rising cresol demand for agrochemicals and pesticides, recent technological developments of cresol market and growth opportunities/investment opportunities. Based on application the market is categorized into antioxidants, chemical intermediates, fragrance, specialty resins, solvents, preservatives and vitamin E. Depending on the product the market is segmented by Meta-cresols, Para-cresols and Ortho-cresols. - The report provides a detailed analysis on current and future market trends to identify the investment opportunities - Market forecasts till 2025, using estimated market values as the base numbers - Key market trends across the business segments, Regions and Countries - Key developments and strategies observed in the market - Market Dynamics such as Drivers, Restraints, Opportunities and other trends - In-depth company profiles of key players and upcoming prominent players - Growth prospects among the emerging nations through 2025 - Market opportunities and recommendations for new investments Key Topics Covered: 1 Market Outline 2 Executive Summary 3 Market Overview 3.1 Current Trends 3.1.1 Rising consumer demand for Vitamin E 3.1.2 Rising cresol demand for Agrochemicals and Pesticides 3.1.3 Recent Technological Developments of Cresol Market 3.1.4 Growth Opportunities/Investment Opportunities 3.2 Drivers 3.3 Constraints 3.4 Industry Attractiveness 3.4.1 Bargaining power of suppliers 3.4.2 Bargaining power of buyers 3.4.3 Threat of substitutes 3.4.4 Threat of new entrants 3.4.5 Competitive rivalry 4 Cresol Market, By Application 4.1 Antioxidants 4.1.1 Antioxidants Market Forecast to 2025 (US$ MN) 4.2 Chemical Intermediates 4.2.1 Chemical Intermediates Market Forecast to 2025 (US$ MN) 220.127.116.11 Agrochemicals & Pesticides 18.104.22.168.1 Agrochemicals & Pesticides Market Forecast to 2025 (US$ MN) 22.214.171.124 Dyes 126.96.36.199.1 Dyes Market Forecast to 2025 (US$ MN) 188.8.131.52 Butylated Hydroxytoluene (BHT) 184.108.40.206.1 Butylated Hydroxytoluene (BHT) Market Forecast to 2025 (US$ MN) 4.3 Fragrance 4.3.1 Fragrance Market Forecast to 2025 (US$ MN) 4.4 Specialty Resins 4.4.1 Specialty Resins Market Forecast to 2025 (US$ MN) 4.5 Solvents 4.5.1 Solvents Market Forecast to 2025 (US$ MN) 4.6 Preservatives 4.6.1 Preservatives Market Forecast to 2025 (US$ MN) 4.7 Vitamin E 4.7.1 Vitamin E Market Forecast to 2025 (US$ MN) 5 Cresol Market, By Product 5.1 Meta-cresols 5.1.1 Meta-cresols Market Forecast to 2025 (US$ MN) 5.2 Para-cresols 5.2.1 Para-cresols Market Forecast to 2025 (US$ MN) 5.3 Ortho-cresols 5.3.1 Ortho-cresols Market Forecast to 2025 (US$ MN) 6 Cresol Market, By Geography 7 Key Player Activities 7.1 Acquisitions & Mergers 7.2 Agreements, Partnerships, Collaborations and Joint Ventures 7.3 Product Launch & Expansions 7.4 Other Activities 8 Leading Companies 8.1 Anhui Haihua Chemical Technology Co. Ltd. 8.2 Ardison Oils & Electricals(P) Ltd 8.3 Atul Ltd. 8.4 Dakota Gasification Company 8.5 Konan Chemical Manufacturing Co. Ltd. 8.6 Lanxess AG 8.7 Merisol Group of Companies 8.8 Mitsui Chemicals Inc. 8.9 Nanjing Datang Chemical Co. Ltd 8.10 Nanjing Long Yan Chemical Co. Ltd. 8.11 RüTGERS Group 8.12 SABIC 8.13 Sasol Limited 8.14 Xiamen Hisunny Chemical Co. Ltd For more information about this report visit http://www.researchandmarkets.com/research/mjjkqv/global_cresol
News Article | February 17, 2017
High Performance Pigments (HPPS) Market to Reach $5.98 Billion With 3.94% CAGR Forecast to 2022Pune, India - February 17, 2017 /MarketersMedia/ — High Performance Pigments (HPPS) Industry Description Wiseguyreports.Com Adds “High Performance Pigments (HPPS) -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2022” To Its Research Database The Global High Performance Pigments market is accounted for $4.56 billion in 2015 and is expected to reach $5.98 billion by 2022 growing at a CAGR of 3.94%. Rising demand for automotive coatings and growing personal care industry particularly in Asia Pacific is expected to remain a key driving factor for the market. Fluctuations in Raw material prices of pigments will pose a challenge to the market growth. Asia Pacific is expected to witness the highest CAGR during the forecast period owing to its applications in cosmetics and automotive coatings including transmission and differential systems. Inorganic high performance pigment segment accounted for the largest share in the market. The growth is attributed to changes in consumer preferences. Request for Sample Report @ https://www.wiseguyreports.com/sample-request/674316-high-performance-pigments-hpps-global-market-outlook-2016-2022 Some of the key players in global high performance pigments market include Atul Ltd., BASF SE, Clariant AG, Ferro Corporation, Vijay Chemical Industries, Gharda Chemicals Limited, Heubach GmbH, Horst Chemicals Zhuhai Co. Ltd., Huntsman International LLC, Lanxess AG, Merck, Eckart Effect Pigments, Solvay SA, Sudarshan Chemical Industries Ltd, Sun Chemical Corporation and Synthesia. A.S. Applications Covered: • Plastics • Coatings o Industrial Coatings o Decorative Coatings o Automotive Coatings • Other Applications Pigment Types Covered: • Inorganic/Metallic High Performance Pigments o Cerium Pigments o Titanate Pigments o Bismuth Vanadate o Cadmium Pigments • Organic High Performance Pigments o Isoindolinones and Isoindolines o Perylenes o Phthalocyanines o Diketo-Pyrrolo-Pyrroles o Benzimidazolones HPPs o Disazo Condensations o Quinacridones o Dioxazine Violet Leave a Query @ https://www.wiseguyreports.com/enquiry/674316-high-performance-pigments-hpps-global-market-outlook-2016-2022 Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=674316 Continued... Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK) Contact Info:Name: NORAH TRENTEmail: Sales@Wiseguyreports.ComOrganization: WISE GUY RESEARCH CONSULTANTS PVT LTDAddress: Pune -40027, Maharashtra, India Phone: +91 841 198 5042Source URL: http://marketersmedia.com/high-performance-pigments-hpps-market-2017-global-analysis-opportunities-and-forecast-to-2022/170848For more information, please visit https://www.wiseguyreports.com/sample-request/674316-high-performance-pigments-hpps-global-market-outlook-2016-2022Source: MarketersMediaRelease ID: 170848